Johnson & Johnson
NYSE:JNJDrug Manufacturers - General
-$4.59 today
- Market cap
- $656.47B
- Beta
- 0.26
- P/E (TTM)
- 26.7
- EPS (TTM)
- $8.60
- Dividend yield
- 2.28%
Volume 7.93M
Average 7.71M
JNJ Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Johnson & JohnsonNYSE: JNJ
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $4.65B rose 26.7% year over year, ahead of the +2.4% change in trailing-twelve-month research & development. Sequentially, it rose 27.3% from the prior quarter. Over 3 fiscal years it compounded at +1.2% a year.
Context
- Research & development amounted to 15.6% of revenue in FY2025, down 3.8 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +26.7% holds above the trailing-twelve-month pace of +2.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 14.67B USD
- Year-over-year change
- -14.9%
- 4-year CAGR
- +0.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 14.67B | -14.9% |
| FY2024 | 2024-12-29 | 17.23B | +14.2% |
| FY2023 | 2023-12-31 | 15.09B | +6.7% |
| FY2022 | 2023-01-01 | 14.14B | -1.0% |
| FY2021 | 2022-01-02 | 14.28B | — |
Research & Development vs competitors
How JNJ compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +2.4% is the 9th highest of 11, against a peer median of +6.2%.
- Research & development amounts to 16.2% of revenue for JNJ, versus a peer median of 20.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $28.35B USD | +65.7% | -2.6% | 42.7% | |
| LTM Sep 2026 | $16.08B USD | +2.4% | +1.2% | 16.2% | |
| LTM Sep 2026 | $15.01B USD | -0.3% | +13.4% | 24.1% | |
| LTM Jun 2026 | $11.28B USD | +9.2% | +5.4% | 20.3% | |
| LTM Jun 2026 | $11.05B USD | +7.0% | -3.0% | 17.3% | |
| LTM Jun 2026 | $10.72B USD | +3.1% | +1.5% | 21.8% | |
| LTM Sep 2026 | $9.96B USD | -25.0% | +11.8% | 15.1% | |
| LTM Jun 2026 | £9.2B GBP | +31.8% | +11.1% | 27.7% | |
| LTM Jun 2026 | €8.11B EUR | +5.4% | +6.5% | 16.6% | |
| LTM Jun 2026 | $7.64B USD | +19.3% | +16.3% | 20.0% | |
| LTM Jun 2026 | $6.07B USD | +2.7% | +5.2% | 19.9% | |
| Peer median (excluding JNJ) | — | +6.2% | +5.9% | 20.2% | |
Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 78.74B | 79.99B | 85.16B | 88.82B | 94.19B |
| Cost of Revenue | 23.4B | 24.6B | 26.55B | 27.47B | 30.26B |
| Gross Profit | 55.34B | 55.39B | 58.61B | 61.35B | 63.94B |
| Gross Margin | 70.3% | 69.3% | 68.8% | 69.1% | 67.9% |
| Research & Development | 14.28B | 14.14B | 15.09B | 17.23B | 14.67B |
| Selling, General & Admin | 20.12B | 20.25B | 20.11B | 21.97B | 23.68B |
| Operating Expenses | 34.4B | 34.38B | 35.2B | 39.2B | 38.34B |
| Depreciation & Amortization | 7.39B | 6.97B | 7.49B | 7.34B | 7.5B |
| EBITDA | 26.75B | 26.61B | 23.32B | 24.78B | 41.06B |
| EBITDA Margin | 34.0% | 33.3% | 27.4% | 27.9% | 43.6% |
| Operating Income | 20.94B | 21.01B | 23.41B | 22.15B | 25.6B |
| Operating Margin | 26.6% | 26.3% | 27.5% | 24.9% | 27.2% |
| Interest Income | 53M | 490M | 1.26B | 1.33B | 1.06B |
| Interest Expense | 183M | 276M | 772M | 755M | 971M |
| Other Income / Expenses | (1.77B) | (1.65B) | (8.35B) | (5.46B) | 6.99B |
| Income Before Tax | 19.18B | 19.36B | 15.06B | 16.69B | 32.58B |
| Pre-Tax Margin | 24.4% | 24.2% | 17.7% | 18.8% | 34.6% |
| Income Tax Expense | 1.38B | 2.99B | 1.74B | 2.62B | 5.78B |
| Net Income | 20.88B | 17.94B | 35.15B | 14.07B | 26.8B |
| Net Margin | 26.5% | 22.4% | 41.3% | 15.8% | 28.5% |
| EPS (Basic) | 7.93 | 6.83 | 13.88 | 5.84 | 11.03 |
| EPS (Diluted) | 7.81 | 6.73 | 13.72 | 5.79 | 11.03 |
| Weighted Avg Shares | 2.63B | 2.61B | 2.53B | 2.41B | 2.43B |
| Weighted Avg Shares (Diluted) | 2.67B | 2.66B | 2.56B | 2.43B | 2.43B |
Johnson & Johnson
NYSE:JNJ
Intrinsic Alpha fair value
Locked
Current Price
$272.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.